- Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA
- Hire represents a major step forward in building world-class pharmaceutical organization capable of meeting significant patient need
MAPS Public Benefit Corporation (MAPS PBC) announced today that Michael Mullette, an experienced drug development and commercialization expert, has joined its senior leadership team as Chief Operating Officer. Mullette most recently served as the Vice President and Managing Director of North America for Moderna, where he oversaw commercialization of the company’s COVID-19 vaccine during the height of the pandemic.
Mike is a highly talented, effective, and mission-driven leader who has repeatedly built teams and organizations that succeed in the face of big and novel challenges, most recently in his work at Moderna. He brings to MAPS PBC a wealth of experience in drug development, expertise in drug commercialization, and a global perspective. With Mike, MAPS PBC is taking another major step in building a world-class pharmaceutical organization capable of meeting the enormous need for novel treatments for PTSD and other mental health conditions. I’m thrilled to expand our team with another experienced partner who shares our values.
Amy Emerson, CEO, MAPS PBC
Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. Prior to his work at Moderna, Mullette developed broad pharmaceutical expertise with Sanofi in a variety of management roles in the U.S., Australia, France, Japan, and Canada. He holds a B.S. in Marketing from Villanova University, and an M.B.A. from Lehigh University.
I am extremely excited to join MAPS PBC as COO at a critical time of growth for the organization. Millions of people living with PTSD today need more effective treatment options, and MAPS PBC is breaking ground with their innovative approach. I look forward to working with the team to bring MDMA-assisted therapy and other potential FDA-approved treatments in our pipeline to help those in need.
Michael Mullette, COO, MAPS PBC
Mullette’s primary responsibilities will include:
- Developing the organization’s long-term vision and strategy alongside the CEO and Board.
- Ensuring the company operates effectively and efficiently across all domains.
- Achieving a successful first-in-class commercial launch in the United States.
- Helping to ensure a high-performing portfolio and psychedelic medicine pipeline.
- Developing and executing a strategy for global expansion and global commercialization of MDMA-assisted therapy.
The Multidisciplinary Association for Psychedelic Studies and its wholly-owned subsidiary MAPS PBC have further invested in team members to build the organization and company:
- Fede Menapace has been named MAPS’ Chief Strategy Officer. For the past two years, Fede has served as MAPS’ Director of Strategy, focusing on organizational growth, financing strategy, and pharma business development. As CSO, the scope of his role will grow to include the development of additional revenue-generating initiatives and MAPS’ global humanitarian efforts to bring psychedelic healing to the countries and populations most in need.
- Steven Huang has joined MAPS as Justice, Equity, Diversity and Inclusion Officer (JEDI), reporting to the Deputy Director. Steven will guide the JEDI Council, a cross-functional team of employees across MAPS and MAPS PBC that guides internal policies and the Health Equity initiative.
- Debra (Deb) De Angelo, Ph.D., has joined MAPS PBC as Head of Medical Affairs. Deb was most recently Senior Director of Medical Affairs at Kaléo and formerly Head of Medical Strategy at Indivior. She will lead the company’s engagement with the medical community through publications, conferences, real-world evidence generation and other means.
- Dawn Lundin, M.S., has joined MAPS PBC as Head of Global Quality Management Systems. Most recently Director of Compliance at the University of Pennsylvania’s Perelman School of Medicine, Dawn previously held senior Quality Assurance roles over the course of two decades at Merck. Dawn remains a faculty member at Penn directing the QA course of study for the ITMAT Masters program. She will oversee the quality systems in support of clinical development activities, ensuring MAPS PBC continues to follow best practice standards
- Theresa Gorenc, M.P.H., has joined MAPS PBC as Head of Market Access. Theresa most recently led market access analytics teams at AbbVie, where she contributed to the success of over 30 different medicines. Theresa is responsible for securing coverage and reimbursement for MAPS PBC’s therapeutics and ensuring accessibility for patients.
###
ABOUT MAPS PUBLIC BENEFIT CORPORATION (MAPS PBC)
MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics while prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. It is the parent company of MAPS EU, formed to organize and administer clinical trials of MDMA-assisted therapy for PTSD in the United Kingdom and European Union.
ABOUT MAPS
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since MAPS was founded, philanthropic donors and grantors have given more than $130 million for psychedelic and marijuana research and education. MAPS has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.
MEDIA CONTACT
Betty Aldworth, Director of Communications
maps.org/newsroom
